suramin has been researched along with Pancreatic Neoplasms in 3 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "DSL-6A/C1 pancreatic cancers were implanted in the pancreas of 109 Lewis rats." | 1.40 | Non-invasive quantification of anti-angiogenic therapy by contrast-enhanced MRI in experimental pancreatic cancer. ( Buhr, HJ; Fischer, S; Hotz, B; Hotz, HG; Raatschen, HJ; Schoenfeld, CO; Zsivcsec, B, 2014) |
| "In vitro, rat ductal pancreatic cancer cells (DSL-6A) were incubated with suramin (10-800 microg/ml), and cell proliferation was assessed." | 1.35 | Intravital microscopic characterization of suramin effects in an orthotopic immunocompetent rat model of pancreatic cancer. ( Buhr, HJ; Hotz, B; Hotz, HG, 2008) |
| "Suramin inhibited the proliferation of pancreatic cancer cells in a dose-dependent manner and reduced viability at high concentrations." | 1.34 | Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer. ( Bhargava, S; Buhr, HJ; Hines, OJ; Hotz, B; Hotz, HG; Reber, HA, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Raatschen, HJ | 1 |
| Fischer, S | 1 |
| Zsivcsec, B | 1 |
| Schoenfeld, CO | 1 |
| Hotz, B | 3 |
| Buhr, HJ | 3 |
| Hotz, HG | 3 |
| Bhargava, S | 1 |
| Hines, OJ | 1 |
| Reber, HA | 1 |
3 other studies available for suramin and Pancreatic Neoplasms
| Article | Year |
|---|---|
Non-invasive quantification of anti-angiogenic therapy by contrast-enhanced MRI in experimental pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizu | 2014 |
Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor | 2007 |
Intravital microscopic characterization of suramin effects in an orthotopic immunocompetent rat model of pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Capillary Permeability; Carcinoma, Pancreat | 2008 |